Royalty Pharma Past Earnings Performance
Past criteria checks 3/6
Royalty Pharma's earnings have been declining at an average annual rate of -40.8%, while the Pharmaceuticals industry saw earnings declining at 2.2% annually. Revenues have been growing at an average rate of 1.3% per year. Royalty Pharma's return on equity is 11.8%, and it has net margins of 35.7%.
Key information
-40.8%
Earnings growth rate
-44.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 1.3% |
| Return on equity | 11.8% |
| Net Margin | 35.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28
Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth
Aug 18Royalty Pharma declares $0.19 dividend
Jul 15Royalty Pharma: Unique Diversification, Bear Market Performer
May 26The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)
Apr 25Royalty Pharma Offers A Unique Long-Term Investment Opportunity
Mar 01Revenue & Expenses BreakdownBeta
How Royalty Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,239 | 799 | 222 | 52 |
| 31 Dec 23 | 2,355 | 1,135 | 250 | 52 |
| 30 Sep 23 | 2,324 | 184 | 264 | 102 |
| 30 Jun 23 | 2,361 | 255 | 257 | 77 |
| 31 Mar 23 | 2,359 | 332 | 261 | 77 |
| 31 Dec 22 | 2,237 | 43 | 227 | 177 |
| 30 Sep 22 | 2,247 | 507 | 200 | 230 |
| 30 Jun 22 | 2,259 | 466 | 198 | 295 |
| 31 Mar 22 | 2,278 | 602 | 191 | 298 |
| 31 Dec 21 | 2,289 | 620 | 183 | 200 |
| 30 Sep 21 | 2,286 | 783 | 187 | 104 |
| 30 Jun 21 | 2,239 | 972 | 189 | 19 |
| 31 Mar 21 | 2,195 | 493 | 187 | 21 |
| 31 Dec 20 | 2,122 | 495 | 182 | 26 |
| 30 Sep 20 | 2,008 | 1,745 | 155 | 34 |
| 30 Jun 20 | 1,934 | 1,863 | 130 | 52 |
| 31 Mar 20 | 1,880 | 2,052 | 117 | 68 |
| 31 Dec 19 | 1,814 | 2,349 | 103 | 83 |
| 31 Dec 18 | 1,795 | 1,378 | 62 | 393 |
| 31 Dec 17 | 1,598 | 1,210 | 106 | 118 |
Quality Earnings: RPRX has a large one-off gain of $318.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: RPRX's current net profit margins (35.7%) are higher than last year (14.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RPRX's earnings have declined by 40.8% per year over the past 5 years.
Accelerating Growth: RPRX's earnings growth over the past year (140.7%) exceeds its 5-year average (-40.8% per year).
Earnings vs Industry: RPRX earnings growth over the past year (140.7%) exceeded the Pharmaceuticals industry 3.7%.
Return on Equity
High ROE: RPRX's Return on Equity (11.8%) is considered low.